Quick Answer
Ernexa Therapeutics Inc. reported Total Revenue of $582.0 thousand for the year ending 2024.
- Ernexa Therapeutics Inc. showed an increase of +755.9% in Total Revenue from 2023 to 2024.
- This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $6.42 million | Q2 2014: $6.87 million | Q3 2014: $6.01 million | Q1 2015: $5.73 million | Q2 2015: $6.19 million | Q3 2015: $6.08 million | Q1 2016: $5.48 million | Q2 2016: $5.41 million | Q3 2016: $5.44 million | Q1 2017: $5.23 million | Q2 2017: $5.55 million | Q2 2017: $5.55 million | Q3 2017: $5.20 million | Q3 2017: $5.20 million | Q1 2018: $5.76 million | Q1 2018: $5.76 million | Q2 2018: $5.65 million | Q3 2018: $6.00 million | Q1 2019: $4.83 million | Q2 2019: $5.23 million | Q3 2019: $4.58 million | Q1 2020: $2.39 million | Q2 2020: $754.0 thousand | Q3 2020: $1.48 million | Q3 2022: $0.00 | Q1 2023: $0.00 | Q3 2023: $51.0 thousand | Q1 2024: $47.0 thousand | Q2 2024: $47.0 thousand | Q3 2024: $487.0 thousand.
- Over the full 12 years of available data (2013 to 2024), Ernexa Therapeutics Inc.'s Total Revenue has declined by 97.5%.
- Historical annual values: Fiscal year 2024: $582.0 thousand | Fiscal year 2023: $68.0 thousand | Fiscal year 2022: $0.00 | Fiscal year 2020: $5.80 million | Fiscal year 2019: $19.81 million | Fiscal year 2018: $23.34 million | Fiscal year 2017: $21.27 million | Fiscal year 2017: $21.27 million | Fiscal year 2016: $22.31 million | Fiscal year 2015: $24.52 million | Fiscal year 2014: $26.05 million | Fiscal year 2013: $23.75 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: